In contrast with placebo, satralizumab reduces the probability of extreme relapse in patients with neuromyelitis optica spectrum dysfunction (NMOSD), in step with investigators. The drug…
In contrast with placebo, satralizumab reduces the probability of extreme relapse in patients with neuromyelitis optica spectrum dysfunction (NMOSD), in step with investigators. The drug…